An update from Theratechnologies ( (TSE:TH) ) is now available.
Theratechnologies reported record financial results for the fiscal year 2024, achieving a positive Adjusted EBITDA of $20 million, surpassing its guidance. The company also recorded a quarterly revenue of $25 million and an annual revenue of $85.9 million. New credit facilities have been secured, freeing up $19 million in cash for 2025, and the company has in-licensed two new Ionis assets in Canada to drive long-term growth. The company faced a temporary supply disruption of EGRIFTA SV® due to a shutdown of its contract manufacturer’s facility, but has resumed distribution after FDA approval to sell newly manufactured batches.
More about Theratechnologies
Theratechnologies Inc. is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. The company is primarily involved in the HIV treatment market and aims to strengthen and scale its commercial business through its HIV portfolio.
YTD Price Performance: 0.82%
Average Trading Volume: 123,174
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $84.78M
Find detailed analytics on TH stock on TipRanks’ Stock Analysis page.